BNP Paribas Financial Markets Grows Stake in Grifols, S.A. (NASDAQ:GRFS)

BNP Paribas Financial Markets boosted its position in shares of Grifols, S.A. (NASDAQ:GRFSFree Report) by 20.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 138,915 shares of the biotechnology company’s stock after acquiring an additional 23,122 shares during the quarter. BNP Paribas Financial Markets’ holdings in Grifols were worth $1,606,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Jump Financial LLC purchased a new stake in shares of Grifols during the 3rd quarter valued at about $136,000. China Universal Asset Management Co. Ltd. increased its holdings in Grifols by 350.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,111 shares of the biotechnology company’s stock valued at $163,000 after buying an additional 10,979 shares during the last quarter. Raymond James & Associates bought a new position in Grifols in the third quarter worth approximately $254,000. NBC Securities Inc. bought a new position in Grifols in the third quarter worth approximately $259,000. Finally, QRG Capital Management Inc. purchased a new position in shares of Grifols during the 3rd quarter worth $303,000.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft downgraded Grifols from a “hold” rating to a “sell” rating in a research report on Tuesday, March 12th.

View Our Latest Report on Grifols

Grifols Stock Performance

NASDAQ GRFS opened at $7.20 on Monday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.29 and a current ratio of 2.79. Grifols, S.A. has a 12 month low of $5.30 and a 12 month high of $12.15. The company’s 50 day moving average is $6.79 and its two-hundred day moving average is $8.12.

Grifols Profile

(Free Report)

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

Recommended Stories

Institutional Ownership by Quarter for Grifols (NASDAQ:GRFS)

Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with's FREE daily email newsletter.